Australia - English - Department of Health (Therapeutic Goods Administration)

hope pharmaceuticals pty ltd - sodium thiosulfate pentahydrate, quantity: 12.5 g - solution - excipient ingredients: water for injections; potassium chloride; boric acid; sodium hydroxide - hope pharmaceuticals sodium thiosulfate injection is indicated as an antidote in the treatment of cyanide poisoning. it is frequently used in conjunction with sodium nitrite.,sodium thiosulfate is also indicated to prevent sodium nitroprusside induced cyanide poisoning.

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - pseudoephedrine hydrochloride, quantity: 60 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; calcium hydrogen phosphate dihydrate - fast, temporary relief from a runny nose and reduce the swollen membranes of the nose and sinuses and helping breathe easier.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - oxycodone hydrochloride, quantity: 5 mg - tablet - excipient ingredients: microcrystalline cellulose; sodium starch glycollate type a; silicon dioxide; lactose monohydrate; maize starch; stearic acid - mayne pharma oxycodone ir is indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - ibuprofen, quantity: 20 mg/ml - oral liquid, suspension - excipient ingredients: saccharin sodium; purified water; sodium benzoate; sodium citrate dihydrate; sodium propyl hydroxybenzoate; maltitol solution; polysorbate 80; xanthan gum; sodium methyl hydroxybenzoate; citric acid monohydrate; flavour; microcrystalline cellulose; carmellose sodium - pharmacy choice ibuprofen children's suspension may be used for the temporary relief of pain and discomfort resulting from headaches, teething, earache and muscle sprains. pharmacy choice ibuprofen children's suspension reduces fever and relieves the discomfort of cold and flu symptoms. pharmacy choice ibuprofen children's suspension may be used to reduce fever after childhood vaccinations.

Australia - English - Department of Health (Therapeutic Goods Administration)

mayne pharma international pty ltd - erythromycin, quantity: 250 mg - capsule, enteric - excipient ingredients: povidone; monobasic potassium phosphate; lactose monohydrate; gelatin; carbon black; sunset yellow fcf; shellac; indigo carmine; purified water; cellacefate; erythrosine; diethyl phthalate - mayne pharma erythromycin is indicated in children and adults for the treatment of the following conditions: upper respiratory tract infections of mild to moderate degree caused by streptococcus pyogenes (group a beta haemolytic streptococci), streptococcus pneumoniae (diplococcus pneumoniae). lower respiratory tract infections of mild to moderate severity caused by streptococcus pyogenes (group a beta hemolytic streptococci), streptococcus pneumoniae (diplococcus pneumoniae), acute and chronic bronchitis, pneumonia. sinusitis caused by streptococcus pneumoniae, streptococcus pyogenes. otitis media due to streptococcus pneumoniae, streptococcus pyogenes. respiratory tract infections due to mycoplasma pneumonia (eaton's agent). skin, and skin structure infections of mild to moderate severity caused by streptococcus pyogenes and staphylococcus aureus (resistant staphylococci may emerge during treatment). bordetella pertussis: erythromycin produces early elimination of the causative organism from the nasopharynx although the clinical course of the disease is not altered; therapeutic doses should be continued for at least 10 days. diphtheria: as an adjunct to antitoxin infections due to corynebacterium diphtheriae, to prevent establishment of carriers and to eradicate the organism in carriers. erythrasma: in the treatment of infections due to corynebacterium minutissimum. infections due to listera monocytogenes. non-gonococcal urethritis: chlamydia trachomatis and ureaplasma urealyticum have been shown to be sensitive to erythromycin and clinical studies have demonstrated its efficacy in urethritis due to these organisms. a minimum of 10 days therapy appears to be required. chlamydia trachomatis infection (excluding non-gonococcal urethritis): erythromycin has been shown to be effective in the treatment of trachoma or inclusion-body conjunctivitis and pneumonia in infants caused by chlamydia trachomatis. campylobacter fetus (subspecies) jejuni: infections due to this organism when antibiotic therapy is indicated. primary syphilis caused by treponema pallidum: erythromycin (oral forms only) is an alternative choice of treatment for primary syphilis in patients allergic to the penicillins. in the treatment of primary syphilis, spinal fluid should be examined before treatment and as part of the followup after therapy. legionnaires' disease caused by legionella pneumophila: although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease. prevention of initial attacks of rheumatic fever: penicillin is considered by the american heart association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of group a beta - haemolytic streptococcal infections of the upper respiratory tract e.g. tonsillitis or pharyngitis). erythromycin is indicated for the treatment of penicillin allergic patients. a therapeutic dose should be administered for 10 days. prevention of recurrent attacks of rheumatic fever: penicillin or sulphonamides are considered by the american heart association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. in patients who are allergic to penicillin and sulphonamides, oral erythromycin is recommended by the american heart association in the long term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). prevention of bacterial endocarditis: although no controlled clinical efficacy trials have been conducted, oral erythromycin has been suggested by the american heart association and the american dental association in a regimen for prophylaxis against bacterial endocarditis in patients sensitive to penicillin who have congenital heart disease, or rheumatic or other acquired valvular heart disease when they undergo dental or surgical procedures of the upper respiratory tract. erythromycin is not suitable prior to genitourinary or gastrointestinal tract surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - paracetamol, quantity: 665 mg - tablet, modified release - excipient ingredients: hypromellose; magnesium stearate; microcrystalline cellulose; silicon dioxide; povidone; pregelatinised maize starch; purified water; croscarmellose sodium; titanium dioxide; macrogol 6000 - pharmacy action paracetamol osteo provides effective relief from persistent pain for up to 8 hours. effective for the relief of persistent pain associated with osteoarthritis and muscular aches and pains such as backache. provides effective temporary relief of pain and discomfort associated with: headache, tension headache, cold and flu, period pain, toothache and pain after dental procedures. reduces fever.

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - esomeprazole magnesium dihydrate, quantity: 21.69 mg - capsule, enteric - excipient ingredients: polysorbate 20; triethyl citrate; mannitol; diacetylated monoglycerides; purified water; sodium benzoate; polysorbate 80; titanium dioxide; sucrose; propylene glycol; sorbic acid; maize starch; octoxinol; dimeticone 350; propyl hydroxybenzoate; purified talc; stearoyl macrogolglycerides; gelatin; hypromellose; methyl hydroxybenzoate; iron oxide yellow; methacrylic acid - ethyl acrylate copolymer (1:1); ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - pharmacy choice esomeprazole heartburn relief is indicated for the symptomatic relief of frequent heartburn, acid regurgitation and other symptoms associated with gastro-oesophageal reflux disease (gord).

Australia - English - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - pseudoephedrine hydrochloride, quantity: 30 mg; paracetamol, quantity: 500.4 mg - tablet, uncoated - excipient ingredients: povidone; pregelatinised maize starch; crospovidone; purified water; magnesium stearate; microcrystalline cellulose; stearic acid - temporary relief of the following cold and flu symptoms: nasal congestion, sinus pain, runny nose, headache and body aches and pains. reduces fever.

Israel - English - Ministry of Health

trima israel pharmaceutical products maabarot ltd - digoxin - tablets - digoxin 0.25 mg - digoxin - cardiac failure:digoxin kern pharma is indicated for the treatment of chronic cardiac failure where the principal cause is systolic dysfunction. the greatest therapeutic benefit is achieved in patients with ventricular dilatation.digoxin kern pharma is specifically indicated where cardiac failure is accompanied by atrial fibrilation.supraventricular arrhythmias:digoxin kern pharma is indicated for the treatment of certain supraventricular arrhythmias, particularly atrial fibrillation and flutter, where its principal beneficial effect is to reduce the ventricular rate.

Israel - English - Ministry of Health

mbi pharma ltd., israel - dexamethasone as sodium phosphate - solution for injection - dexamethasone as sodium phosphate 4 mg/ml - dexamethasone - dexamethasone kern pharma is indicated in the treatment of:• endocrine diseases such as nonsuppurative thyroiditis, hypercalcaemia associated with cancer and congenital adrenal hyperplasia.• allergy: severe or disabling allergic conditions resistant to conventional treatments, as in: bronchial asthma, contact or atopical dermatitis, seasonal or perennial allergic rhinitis, hypersensitivity reactions to drugs.• ophtalmic: serious inflammatory and allergic processes, acute and chronic, affecting the eyes, such as: iritis and iridocyclitis, chorioretinitis, choroiditis and diffuse posterior uveitis, optical neuritis, allergic conjunctivitis, allergic marginal corneal ulcers.• inflammatory bowel dis.: systemic treatment in exacerbations of ulcerative colitis and regional enteritis.• dermatological diseases (pemphigus, stevens johnson syndrome, exfoliative dermatitis, severe psoriasis and mycosis fungoides) • respiratory diseases (symptomatic sarcoidosis, berylliosis, loeffler's syndrome)• haematologica